Literature DB >> 10571206

In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.

R A Miller1, K Woodburn, Q Fan, M F Renschler, J L Sessler, J A Koutcher.   

Abstract

PURPOSE: Gadolinium texaphyrin (Gd-Tex, PCI-0120) is an expanded porphyrin that has demonstrated radiation enhancement. In this study, we evaluated the radiation enhancement and biolocalization of Gd-Tex in three animal tumor models. METHODS AND MATERIALS: EMT6, SMT-F, and MCa tumors were established intramuscularly or subcutaneously. Gd-Tex and other metallotexaphyrins were administered prior to single or multiple fractions of radiation. 14C-labeled Gd-Tex was used for biolocalization studies.
RESULTS: Gd-Tex, in combination with radiation, produced significant tumor growth delay compared to irradiated control groups in both single and multifraction radiation studies. Gd-Tex radiation enhancement was observed only when the drug was given before, but not after irradiation. Several metallotexaphyrins, identical except for the metal ion, were studied in the EMT6 tumor model including gadolinium (Gd), lutetium (Lu), europium (Eu), yttrium (Y), and cadmium (Cd) texaphyrin complexes. Only Gd-Tex produced radiation enhancement. Biodistribution studies using 14C-labeled Gd-Tex demonstrated drug selectivity and retention in tumors growing intramuscularly compared to uninvolved muscle and plasma.
CONCLUSIONS: Gd-Tex produces reproducible radiation enhancement in a variety of in vivo tumor models. This drug's unique radiochemistry, tumor selectivity, and in vivo activity suggests possible mechanisms of action not addressed by in vitro assay methods.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571206     DOI: 10.1016/s0360-3016(99)00274-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

1.  Bismuth- and lead-texaphyrin complexes: towards potential α-core emitters for radiotherapy.

Authors:  Christian Preihs; Jonathan F Arambula; Vincent M Lynch; Zahid H Siddik; Jonathan L Sessler
Journal:  Chem Commun (Camb)       Date:  2010-10-04       Impact factor: 6.222

2.  Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.

Authors:  Jonathan F Arambula; Jonathan L Sessler; Zahid H Siddik
Journal:  Bioorg Med Chem Lett       Date:  2011-01-26       Impact factor: 2.823

3.  Porphyrinoid Drug Conjugates.

Authors:  Jonathan F Arambula; Jonathan L Sessler
Journal:  Chem       Date:  2020-07-09       Impact factor: 22.804

4.  Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.

Authors:  Kristin A Bradley; Tianni Zhou; Rene Y McNall-Knapp; Regina I Jakacki; Adam S Levy; Gilbert Vezina; Ian F Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-22       Impact factor: 7.038

5.  Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin) in CD1 mice following intravenous and intraperitoneal injection.

Authors:  G W Boswell; D R Miles; P A Thiemann; M Mesfin
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

Review 6.  Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer.

Authors:  Sayana R Thomas; Deepak Khuntia
Journal:  Int J Nanomedicine       Date:  2007

7.  Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.

Authors:  Grégory Thiabaud; Jonathan F Arambula; Zahid H Siddik; Jonathan L Sessler
Journal:  Chemistry       Date:  2014-06-24       Impact factor: 5.236

8.  Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins.

Authors:  Longhua Qiu; Feng Zhang; Yaoping Shi; Zhibin Bai; Jianfeng Wang; Yonggang Li; Donghoon Lee; Christopher Ingraham; Xiaoyuan Feng; Xiaoming Yang
Journal:  Radiology       Date:  2015-11-24       Impact factor: 11.105

Review 9.  Severe radiation therapy-related soft tissue toxicity in a patient with porphyria cutanea tarda: a literature review.

Authors:  G Brandon Gunn; Karl E Anderson; Abhilasha J Patel; Juan Gallegos; Csilla Kormos Hallberg; Gagan Sood; Sandra S Hatch; Giuseppe Sanguineti
Journal:  Head Neck       Date:  2010-08       Impact factor: 3.147

10.  MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain.

Authors:  Genevieve N Wu; Judith M Ford; Jeffry R Alger
Journal:  J Neurooncol       Date:  2006-03-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.